All Articles

Agoda is selling serenity by promoting Asia's 'hidden' retreats. But as the wellness travel market booms, what is the true cost for these fragile destinations?

National Bank is raising $600M with complex notes offering a 6% yield. We dissect the deal, revealing the strategic gains and the risks investors must weigh.

Agoda data reveals a surge in solo travel in Taiwan, redefining 'Love Day' and signaling a powerful economic shift towards individual-centric experiences.

Rokid's $4M Makuake success isn't just a record; it's a signal. With AI translation as the killer app, are smart glasses finally moving from niche to necessary?

Portable oxygen offers freedom, but as companies market summer travel, a closer look reveals that not all devices may deliver on their life-sustaining promise.

Hong Kong's NatureU touts impressive anti-aging results on a public registry, but a closer look reveals a complex strategy blending early science with savvy marketing.

Sleep is now a bankable asset. A new wave of research is changing how high-stakes industries like aviation manage fatigue, turning rest into a strategic advantage.

A junior explorer just raised millions to follow up on a stunning 2013 gold find. Is it a long shot, or a savvy play on Saskatchewan's resource boom?

A recall of Target's popular baby wipes over dangerous bacteria raises critical questions about private label safety, supplier oversight, and consumer trust.

At Shanghai's CHINA CYCLE expo, CST Tires unveiled more than just lightweight tech; it showcased a strategic pivot that could redefine global manufacturing.

Horizon Growth's new CEO isn't just a management change; it's the final piece in a year-long transformation from a niche carbon firm to a diversified investor.

In a city chasing luxury, one iconic resort is doubling down on affordability and classic fun. We explore how Circus Circus is innovating by looking back.

Ottawa's first national eye care strategy isn't just about health. It's a calculated investment in economic resilience and systemic stability for an aging nation.

The Stoneport Commodity ETF is liquidating after just seven months. Its story reveals the harsh, unsentimental system governing the competitive ETF market.

Digital health firm Osara Health is targeting the 'Cancer Care Cliff,' backing its new survivorship program with a validated 25:1 ROI and proven health outcomes.

The 10-year extension for the Las Vegas Grand Prix is more than a race deal; it's a high-stakes maneuver cementing F1's US strategy amid local growing pains.

A new, ultra-premium bourbon honors Secretariat's greatest win. But this is more than a drink; it's a case study in legacy, luxury, and market disruption.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

Fifteen high schoolers, mentored by racing icons, turned a Harley Nightster into a track-ready beast, proving the power of hands-on technical education.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?